Blood biomarkers, such as elevated levels of certain white blood cells and other markers of inflammation, may help doctors predict…
Articles by Margarida Maia PhD
Screening is ongoing for adults with active axial spondyloarthritis or axSpA, including ankylosing spondylitis, for a Phase 2 clinical…
Most adults with active ankylosing spondylitis or non-radiographic axial spondyloarthritis who achieved low or no disease activity after four…
Certain gut bacteria may influence disease risk in ankylosing spondylitis (AS), with some bacteria associated with a protective effect…
Inflammation in people with axial spondyloarthritis (axSpA), which includes ankylosing spondylitis, is linked to multiple risk factors for cardiovascular…
Rinvoq (upadacitinib) appears to be the most effective treatment to reduce disease activity in people with ankylosing spondylitis…
Both nonsteroidal anti-inflammatory drugs (NSAIDs) and more advanced medications appear to keep disease activity and structural damage under control in…
Tumor necrosis factor inhibitors (TNFi) appear to work as well and be as safe for adults with late-onset ankylosing…
Tapering off a TNF inhibitor — part of a class of medications that block pro-inflammatory molecules — may raise the…
Sarcopenia, a gradual loss of muscle mass and strength, may happen at a rather young age in people with…